Ozempic vs. Farxiga

See how Ozempic and Farxiga compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Ozempic is a once-weekly injectable GLP-1 drug, while Farxiga is a once-daily oral SGLT2 inhibitor from a different drug class.

  • Both reduce cardiovascular and kidney risks in type 2 diabetes, but only Farxiga is FDA-approved to directly treat heart failure.

  • Ozempic is commonly used off-label for weight loss, while Farxiga is not typically prescribed for that purpose.

Ozempic vs. Farxiga Drug Summary

Ozempic

Ozempic is a GLP-1 receptor agonist approved to control blood sugar in adults with type 2 diabetes, alongside diet and exercise. It also reduces cardiovascular risk in people with type 2 diabetes and existing heart disease, and slows kidney damage in type 2 diabetics with chronic kidney disease. It is given as a once-weekly injection, starting at a low dose that increases gradually over several weeks.

Farxiga

Farxiga is an SGLT2 inhibitor that lowers blood sugar in adults and children 10 and older with type 2 diabetes by helping the kidneys remove excess glucose in urine. It is also approved to treat heart failure and to slow chronic kidney disease progression, even in people without diabetes. It is taken as a once-daily oral tablet.

Ozempic vs. Farxiga Side Effects

Ozempic

Most common
Nausea (up to 20.3%)
Vomiting (up to 9.2%)
Diarrhea (up to 8.8%)
Abdominal pain (up to 7.3%)

Farxiga

Most common
Female genital yeast infection (up to 6.9%)
Nasopharyngitis (up to 6.3%)
Urinary tract infections (up to 4.3%)
Back pain (up to 4.2%)

Ozempic vs. Farxiga Dosage

Ozempic

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.25 mg once weekly Weeks 1-4
Maximum dose 2 mg once weekly If needed
Dose changes 3 increases Every 4 weeks

Farxiga

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 5 mg once daily At the start
Maximum dose 10 mg once daily If needed
Dose changes 1 increase As tolerated

Ozempic vs. Farxiga Indications

Ozempic

Ozempic is FDA-approved to improve blood sugar control in adults with type 2 diabetes, along with diet and exercise. It also carries approvals for reducing cardiovascular risk in people with existing heart disease and for slowing chronic kidney disease progression. Many providers also prescribe it off-label for weight loss, though that specific use is FDA-approved only for Wegovy, semaglutide's higher-dose version.

  • Blood sugar control in type 2 diabetes

  • Reduce cardiovascular risk with known heart disease

  • Slow chronic kidney disease progression

  • Off-label: weight loss in people without diabetes

Farxiga

Farxiga is FDA-approved to control blood sugar in adults and children 10 and older with type 2 diabetes. It is also approved to treat heart failure across the full range of ejection fractions and to slow chronic kidney disease progression, independent of diabetes status. These broad approvals make it a common choice for patients with overlapping heart, kidney, and metabolic conditions.

  • Blood sugar control in type 2 diabetes, ages 10+

  • Reduce heart failure hospitalization risk

  • Treat heart failure, reduced or preserved function

  • Slow chronic kidney disease progression

Ozempic vs. Farxiga Pros and Cons

Ozempic

Ozempic's GLP-1 mechanism curbs appetite and slows digestion, producing meaningful weight loss as a side benefit for many patients with type 2 diabetes. It requires a weekly injection and carries a boxed warning for thyroid tumors seen in animal studies. Coverage for its diabetes indications is generally solid, though the off-label weight-loss use is rarely reimbursed.

Pros

  • Produces significant weight loss as a bonus effect

  • Once-weekly dosing means just one injection a week

  • FDA-approved to reduce heart attack and stroke risk

  • Slows chronic kidney disease progression in diabetes

Cons

  • Requires a self-administered injection, not a pill

  • GI side effects like nausea are common

  • Boxed warning for thyroid C-cell tumors in animals

  • Higher list price, roughly $935 to $1,043 a month before insurance

Farxiga

Farxiga works by causing the kidneys to remove excess glucose in urine, offering a convenient oral option with proven benefits for heart failure and kidney disease beyond glucose control. It carries a real risk of genital infections and, rarely, a serious infection called Fournier's gangrene. Its lower list price and broad FDA approvals make it a versatile option for patients with overlapping conditions.

Pros

  • Oral tablet, no injections needed

  • Lower list price, roughly $400 to $785 a month before insurance

  • Approved for heart failure across ejection fraction types

  • Approved for children as young as 10 with type 2 diabetes

Cons

  • Genital yeast infections are common with this drug class

  • Rare risk of Fournier's gangrene, a serious infection

  • Can cause ketoacidosis even with near-normal blood sugar

  • Not associated with the significant weight loss seen with Ozempic

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.